The recent announcement by the Innovation Center at the Center for Medicare and Medicaid Services regarding the launch of an Oncology Care Model is an important step toward patient-centered cancer care.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
